COLOPL Group Company Brilliantcrypto Inc., Reveals “Brilliantcrypto,” The Blockchain Game Which Generates Economic Value in The Metaverse With Digital World Gemstones
25.7.2023 08:00:00 EEST | Business Wire | Press release
The wholly owned subsidiary of COLOPL, Inc. (HQ: Minato City Tokyo; CEO: Takashi Miyamoto), Brilliantcrypto, Inc. (HQ: Minato City Tokyo; CEO: Naruatsu Baba), announced its new blockchain game “Brilliantcrypto,” which introduces the new “Proof of Gaming” concept at the global Web3 conference “WebX” (held on 25/07/2023).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230724611315/en/
New blockchain game "Brilliantcrypto" (Graphic: Business Wire)
Game Overview
Brilliantcrypto is a blockchain game where players around the world become miners and excavate the mines with the aim of finding gemstones and tokens. Users buy pickaxes in the in-game marketplace, and use items like the “detector” while carrying out mining. By mining, players can obtain tokens and gemstones, and there will be the possibility to bring the gemstones, which can turn into NFTs, into many different metaverse worlds. There will also be the possibility to buy and sell the gemstones, as well as use them.
What is “Proof of Gaming”?
Simply put, “Proof of Gaming” is the game model version of “Proof of Work,” which is Bitcoin’s consensus algorithm.
In Bitcoin, mining is carried out in the form of a tremendous amount of hash calculations, which in turn guarantees value on the blockchain. Similarly, in Brilliantcrypto, mining will be carried out in the form of people throughout the world playing the game, which will guarantee the value of gemstones in the digital world.
Generating Economic Value In the Metaverse with “Proof of Gaming”
The metaverse is currently being developed, and we believe that one reason that could be given for it not fully catching on yet is that there is currently no “economic value.” If the value of digital world gemstones is guaranteed by “Proof of Gaming,” it becomes possible to use them not only in-game, but also in many different metaverse worlds, and so becomes possible to exchange them and use them. Therefore, the more exchanges begin to take place, the more the demand for gemstones with value will grow, and the more people from around the world will gather to play the game. We believe that through this cycle, “Proof of Gaming” will be activated further and as a result, true economic value will be generated in the metaverse.
Realizing Sustainable Play-to-Earn
In recent years, “play-to-earn,” which made it possible to earn money while playing games using a combination of blockchain technology and cryptocurrency, has been gathering global attention.
On the other hand, there has existed a sustainability issue with play-to-earn, as the system only allows individual, early adopters to actually make a profit. Through guaranteeing the value of digital world gemstones with Brilliantcrypto’s “Proof of Gaming” model, societal value will be generated and brought out into the world. That is why we believe sustainable play-to-earn can finally be made a reality.
About the Closed Beta Test
We will carry out a closed beta test before the official service launch.
Therefore, from today until Monday 08/08/2023 05:59 (UTC), we are accepting applications to participate in the beta.
Closed Beta Details
- Application Period: Tues. 25/07/2023 05:00 〜 Tues. 08/08/2023 05:59 (UTC)
- Amount of spots: Limited availability expected
- Beta Test Period:
1st Test: Tues. 15/08/2023 06:00 - Tues. 22/08/2023 05:59 (UTC)
2nd Test: Tues. 12/09/2023 06:00 - Tues. 19/09/2023 05:59 (UTC)
3rd Test: Tues. 10/10/2023 06:00 - Tues. 17/10/2023 05:59 (UTC)
- Clear Reward (1): Win ¥5000 worth of ETH (receivable by all who clear)
- Clear Reward (2): Enter a lottery, where 6 lucky players will win 2 VIP tickets to watch PSG play in France, in the tournament that decides the top European football team (return flight tickets included).
Closed Beta Application Page
https://beta-user-registration.brilliantcrypto.net
Game Website
https://brilliantcrypto.net
Social Media
- Twitter https://twitter.com/Brypto_Official
- Discord https://discord.gg/x23GWNu73B
- Youtube https://www.youtube.com/@Brilliantcrypto
Company Name: Brilliantcrypto, Inc.
Headquarters: Tokyo, Minato City, Akasaka 9-7-2, 5F & 6F Midtown East
Founded: 2022/11/09
Executive Director: Naruatsu Baba
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230724611315/en/
Contact information
Point of Contact regardings inquiries from the media on this release
Brilliantcrypto PR Representative: Hugo Church, Naoki Nose, Yasuhiro Noguchi
Mail：press.contact@brilliantcrypto.net
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom